Lesurf et al. provided clear evidence that HER2-positive breast cancers classified as HER2-enriched achieved significantly higher rates of complete remission when compared to those as luminal A, luminal B, or basal-like [87]. This evidence concerns the gene ERBB2 and breast cancer.